Top

Published in:

Open Access 01-10-2020 | Acute Lymphoblastic Leukemia | Review Article

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies

Authors: Andreas Viardot, Franco Locatelli, Julia Stieglmaier, Faraz Zaman, Elias Jabbour

Published in: Annals of Hematology | Issue 10/2020

Abstract

The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is approved for relapsed/refractory B cell precursor acute lymphoblastic leukemia and B cell precursor acute lymphoblastic leukemia with minimal residual disease. Blinatumomab is also being evaluated in combination with other agents (tyrosine kinase inhibitors, checkpoint inhibitors, and chemotherapy) in various treatment settings, including frontline protocols. An extended half-life BiTE molecule is also under investigation. Patients receiving blinatumomab may experience cytokine release syndrome and neurotoxicity; however, these events may be less frequent and severe than in patients receiving other CD19-targeted immunotherapies, such as chimeric antigen receptor T cell therapy. We review BiTE technology for treating malignancies that express CD19, analyzing the benefits and limitations of this bispecific T cell engager platform from clinical experience with blinatumomab.

Scheuermann RH, Racila E (1995) CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 18(5-6):385–397. https://doi.org/10.3109/10428199509059636CrossRefPubMed

Morphosys (2020) Tafasitamab (MOR208). https://www.morphosys.com/pipeline/proprietary-portfolio/tafasitamab-mor208. Accessed 9 March 2020

Lamb YN (2017) Inotuzumab ozogamicin: first global approval. Drugs 77(14):1603–1610. https://doi.org/10.1007/s40265-017-0802-5CrossRefPubMed

American Cancer Society Typical treatment of acute lymphocytic leukemia (ALL). https://www.cancer.org/cancer/acute-lymphocytic-leukemia/treating/typical-treatment.html. Accessed July 11 2019

American Cancer Society Targeted therapy for acute lymphocytic leukemia (ALL). https://www.cancer.org/cancer/acute-lymphocytic-leukemia/treating/targeted-therapy.html. Accessed July 11 2019

National Comprehensive Cancer Network (2019) NCCN clinical practice guidelines in oncology (NCCN Guidelines®) acute lymphoblastic leukemia version 2.2019. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed August 19 2019

Gökbuget N (2013) How I treat older patients with ALL. Blood 122(8):1366–1375. https://doi.org/10.1182/blood-2012-07-379016CrossRefPubMed

Lee KJ, Chow V, Weissman A, Tulpule S, Aldoss I, Akhtari M (2016) Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults. Ther Clin Risk Manag 12:1301–1310. https://doi.org/10.2147/TCRM.S84261CrossRefPubMedPubMedCentral

Brüggemann M, Kotrova M (2017) Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Hematol Am Soc Hematol Educ Program 2017(1):13–21. https://doi.org/10.1182/asheducation-2017.1.13CrossRef

10.

Gökbuget N (2016) Treatment of older patients with acute lymphoblastic leukemia. Hematology 2016(1):573–579. https://doi.org/10.1182/asheducation-2016.1.573CrossRefPubMed

11.

Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373(16):1541–1552. https://doi.org/10.1056/NEJMra1400972CrossRefPubMed

12.

Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109(3):944–950. https://doi.org/10.1182/blood-2006-05-018192CrossRefPubMed

13.

Jabbour E, O'Brien S, Konopleva M, Kantarjian H (2015) New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 121(15):2517–2528. https://doi.org/10.1002/cncr.29383CrossRefPubMed

14.

Locatelli F, Schrappe M, Bernardo ME, Rutella S (2012) How I treat relapsed childhood acute lymphoblastic leukemia. Blood 120(14):2807–2816. https://doi.org/10.1182/blood-2012-02-265884CrossRefPubMed

15.

Coiffier B, Sarkozy C (2016) Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematol Am Soc Hematol Educ Program 2016(1):366–378. https://doi.org/10.1182/asheducation-2016.1.366CrossRef

16.

Epperla N, Hamadani M (2017) Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances. Hematol Oncol Stem Cell Ther 10(4):277–284. https://doi.org/10.1016/j.hemonc.2017.05.004CrossRefPubMed

17.

Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184–4190. https://doi.org/10.1200/JCO.2010.28.1618CrossRefPubMedPubMedCentral

18.

Chavez JC, Bachmeier C, Kharfan-Dabaja MA (2019) CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol 10:2040620719841581. https://doi.org/10.1177/2040620719841581CrossRefPubMedPubMedCentral

19.

BLINCYTO® (blinatumomab) [prescribing information] (2019). Amgen, Thousand Oaks, CA

20.

Yuraszeck T, Kasichayanula S, Benjamin JE (2017) Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment. Clin Pharmacol Ther 101(5):634–645. https://doi.org/10.1002/cpt.651CrossRefPubMedPubMedCentral

21.

Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69(12):4941–4944. https://doi.org/10.1158/0008-5472.CAN-09-0547CrossRefPubMed

22.

Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS (2015) Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 35(Suppl):S185–S198. https://doi.org/10.1016/j.semcancer.2015.03.004CrossRefPubMed

23.

Nagorsen D, Kufer P, Baeuerle PA, Bargou R (2012) Blinatumomab: a historical perspective. Pharmacol Ther 136(3):334–342. https://doi.org/10.1016/j.pharmthera.2012.07.013CrossRefPubMed

24.

Lorenczewski G, Friedrich M, Kischel R, Dahlhoff K, Anlahr J, Balazs M, Rock D, Boyle MC, Goldstein R, Coxon A, Chapman-Arvedson T (2017) Generation of a half-life extended anti-CD19 BiTE® antibody construct compatible with once-weekly dosing for treatment of CD19-positive malignancies. Blood 130(Supplement 1):2815. https://doi.org/10.1182/blood.V130.Suppl_1.2815.2815CrossRef

25.

Popplewell L, Verhoef G, Kuruvilla J, Tuglus C, Kischel R, Stieglmaier J, Ghobadi A (2019) A first-in-human study of a half-life extended CD19-targeting bite in relapsed/refractory diffuse large B cell lymphoma, mantle cell lymphoma or follicular lymphoma. Hematol Oncol 37(S2):566–567. https://doi.org/10.1002/hon.14_2632CrossRef

26.

Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J, Zhang A, Nagorsen D, Bargou RC (2016) Phase 2 study of bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B cell lymphoma. Blood 127(11):1410–1416. https://doi.org/10.1182/blood-2015-06-651380CrossRefPubMedPubMedCentral

27.

Stein A, Franklin JL, Chia VM, Arrindell D, Kormany W, Wright J, Parson M, Amouzadeh HR, Choudhry J, Joseph G (2019) Benefit-risk assessment of blinatumomab in the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Drug Saf 42(5):587–601. https://doi.org/10.1007/s40264-018-0760-1CrossRefPubMed

28.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625–638. https://doi.org/10.1016/j.bbmt.2018.12.758CrossRefPubMed

29.

Slaney CY, Wang P, Darcy PK, Kershaw MH (2018) CARs versus BiTEs: a comparison between T cell–redirection strategies for cancer treatment. Cancer Discov 8:924–934. https://doi.org/10.1158/2159-8290.cd-18-0297CrossRefPubMed

30.

Frey N, Porter D (2016) Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2016(1):567–572CrossRef

31.

Stein AS, Larson RA, Schuh AC, Stevenson W, Lech-Maranda E, Tran Q, Zimmerman Z, Kormany W, Topp MS (2018) Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv 2(13):1522–1531. https://doi.org/10.1182/bloodadvances.2018019034CrossRefPubMedPubMedCentral

32.

YESCARTA™ [prescribing information] (2017) Kite Pharma Inc, Santa Monica, CA

33.

Khadka RH, Sakemura R, Kenderian SS, Johnson AJ (2019) Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy 11(10):851–857. https://doi.org/10.2217/imt-2019-0074CrossRefPubMed

34.

Porter D, Frey N, Wood PA, Weng Y, Grupp SA (2018) Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol 11(1):35. https://doi.org/10.1186/s13045-018-0571-yCrossRefPubMedPubMedCentral

35.

von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L (2016) Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 34(36):4381–4389. https://doi.org/10.1200/jco.2016.67.3301CrossRef

36.

Coyle L, Morley NJ, Rambaldi A, Mason KD, Verhoef G, Furness C, Zhang A, Jung AS, Franklin JL (2018) Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Blood 132(Suppl 1):400. https://doi.org/10.1182/blood-2018-99-112280CrossRef

37.

Katz DA, Chu MP, David KA TC, Morley NJ, Khan SS, Chen Y, Kalabus J, Morris J, Anderson A, Avilion AA, Gonzalez-Barca E (2019) Open-label, phase 2 study of blinatumomab after first-line rituximab-chemotherapy in adults with newly diagnosed, high-risk diffuse large B-cell lymphoma. Paper presented at the American Society of Hematology, San Diego, CA, USA

38.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531–2544. https://doi.org/10.1056/NEJMoa1707447CrossRefPubMedPubMedCentral

39.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT (2018) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45–56. https://doi.org/10.1056/NEJMoa1804980CrossRefPubMed

40.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439–448. https://doi.org/10.1056/NEJMoa1709866CrossRefPubMedPubMedCentral

41.

Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664–679. https://doi.org/10.1158/2159-8290.cd-16-0040CrossRefPubMedPubMedCentral

42.

Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R (2018) FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23(8):943–947. https://doi.org/10.1634/theoncologist.2018-0028CrossRefPubMedPubMedCentral

43.

Frey N (2017) Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol 30(4):336–340. https://doi.org/10.1016/j.beha.2017.09.002CrossRefPubMed

44.

Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522–1531. https://doi.org/10.1182/blood-2017-08-798322CrossRefPubMedPubMedCentral

45.

Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foà R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Brüggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16(1):57–66. https://doi.org/10.1016/s1470-2045(14)71170-2CrossRefPubMed

46.

Jain T, Litzow MR (2018) No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Adv 2(22):3393–3403. https://doi.org/10.1182/bloodadvances.2018020198CrossRefPubMedPubMedCentral

47.

Klinger M, Zugmaier G, Nägele V, Goebeler ME, Brandl C, Stelljes M, Lassmann H, von Stackelberg A, Bargou RC, Kufer P (2019) Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events. Cancer Res. Epub ahead of print. https://doi.org/10.1158/0008-5472.can-19-1131

48.

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836–847. https://doi.org/10.1056/NEJMoa1609783CrossRefPubMedPubMedCentral

49.

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, Doubek M, Fielding AK, Giebel S, Haddad V, Hoelzer D, Holland C, Ifrah N, Katz A, Maniar T, Martinelli G, Morgades M, O'Brien S, Ribera JM, Rowe JM, Stein A, Topp M, Wadleigh M, Kantarjian H (2016) Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473. https://doi.org/10.1038/bcj.2016.84CrossRefPubMedPubMedCentral

50.

Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, Sridhara R, Deisseroth A, Philip R, Farrell AT, Pazdur R (2019) FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clin Cancer Res 25(2):473–477. https://doi.org/10.1158/1078-0432.ccr-18-2337CrossRefPubMed

51.

Dombret H, Topp MS, Schuh AC, Wei AH, Durrant S, Bacon CL, Tran Q, Zimmerman Z, Kantarjian H (2019) Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 60(9):2214–2222. https://doi.org/10.1080/10428194.2019.1576872CrossRefPubMed

52.

Jabbour EJ, Gokbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS (2019) Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer 125(23):4181–4192. https://doi.org/10.1002/cncr.32335CrossRefPubMed

53.

Topp MS, Zimmerman Z, Cannell P, Dombret H, Maertens J, Stein A, Franklin J, Tran Q, Cong Z, Schuh AC (2018) Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood 131(26):2906–2914. https://doi.org/10.1182/blood-2017-09-804658CrossRefPubMedPubMedCentral

54.

Pulte ED, Vallejo J, Przepiorka D, Nie L, Farrell AT, Goldberg KB, McKee AE, Pazdur R (2018) FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia. Oncologist 23(11):1366–1371. https://doi.org/10.1634/theoncologist.2018-0179CrossRefPubMedPubMedCentral

55.

Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Topp MS, Fielding AK, Rambaldi A, Ritchie EK, Papayannidis C, Sterling LR, Benjamin J, Stein A (2017) Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome–positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 35(16):1795–1802. https://doi.org/10.1200/jco.2016.69.3531CrossRefPubMed

56.

Amgen (2019) Amgen announces positive results from two phase 3 BLINCYTO® (blinatumomab) studies in pediatric patients with relapsed acute lymphoblastic leukemia. Amgen, Thousand Oaks, California

57.

Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, Schlegel P, Bourquin J, Handgretinger R, Brethon B, Rossig C, Chen-Santel C (In press) Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J

58.

Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M (2017) Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood 129(5):572–581. https://doi.org/10.1182/blood-2016-07-726588CrossRefPubMedPubMedCentral

59.

Tasian SK, Loh ML, Hunger SP (2017) Philadelphia chromosome–like acute lymphoblastic leukemia. Blood 130(19):2064–2072. https://doi.org/10.1182/blood-2017-06-743252CrossRefPubMedPubMedCentral

60.

Minson KA, Prasad P, Vear S, Borinstein S, Ho R, Domm J, Frangoul H (2013) t(17;19) in children with acute lymphocytic leukemia: a report of 3 cases and a review of the literature. Case Rep Hematol 563291:1–4. https://doi.org/10.1155/2013/563291CrossRef

61.

Mouttet B, Vinti L, Ancliff P, Bodmer N, Brethon B, Cario G, Chen-Santel C, Elitzur S, Hazar V, Kunz J, Möricke A, Stein J, Vora A, Yaman Y, Schrappe M, Anak S, Baruche A, Locatelli F, von Stackelberg A, Stanulla M, Bourquin JP (2019) Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica 104(6):e244–e247. https://doi.org/10.3324/haematol.2018.210104CrossRefPubMedPubMedCentral

62.

Schwartz MS, Jeyakumar D, Damon LE, Schiller GJ, Wieduwilt MJ (2019) A phase I/II study of blinatumomab in combination with pembrolizumab for adults with relapsed refractory B-lineage acute lymphoblastic leukemia: University of California Hematologic Malignancies Consortium Study 1504. J Clin Oncol 37(15_suppl):TPS7064. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS7064CrossRef

63.

Webster J, Luskin MR, Prince GT, DeZern AE, DeAngelo DJ, Levis MJ, Blackford A, Sharon E, Streicher H, Luznik L, Gojo I (2018) Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed/refractory (R/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL): preliminary results of a phase I study. Blood 132(Suppl 1):557. https://doi.org/10.1182/blood-2018-99-111845CrossRef

64.

Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E (2017) Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk 17(12):897–901. https://doi.org/10.1016/j.clml.2017.08.101CrossRefPubMed

65.

King AC, Pappacena JJ, Tallman MS, Park JH, Geyer MB (2019) Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. Leuk Res 79:27–33. https://doi.org/10.1016/j.leukres.2019.02.009CrossRefPubMed

66.

Chiaretti S, Bassan R, Vitale A, Elia L, Piciocchi A, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Salutari P, Mancino A, Vignetti M, Rambaldi A, Foà R (2019) A dasatinib-blinatumomab combination for the front-line treatment of adult Ph+ALL patients preliminary results of the GIMEMA LAL2116 D-ALBA trial; on behalf of GIMEMA acute leukemia working party. Paper presented at the European Hematology Association, June 16

67.

Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM (2019) Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis. Cancer 125(15):2579–2586. https://doi.org/10.1002/cncr.32139CrossRefPubMedPubMedCentral

68.

Sasaki K, Kantarjian HM, Ravandi F, Short NJ, Kebriaei P, Huang X, Rytting ME, Jain N, Konopleva MY, Garcia-Manero G, Champlin RE, Kadia TM, Cortes JE, Estrov ZE, Takahashi K, Mace M, Khouri M, Nasnas P, Jacob J, Garris RE, Jabbour EJ (2018) Sequential combination of low-intensity chemotherapy (mini-hyper-CVD) plus inotuzumab ozogamicin with or without blinatumomab in patients with relapsed/refractory philadelphia chromosome-negative acute lymphoblastic leukemia (ALL): a phase 2 trial. Blood 132(Suppl 1):553. https://doi.org/10.1182/blood-2018-99-115162CrossRef

69.

Advani A, Moseley A, O'Dwyer K, Wood B, Fang M, Wieduwilt M, Aldoss I, Park J, Klisovic R, Baer M, Stock W, Bhave R, Othus M, Litzow M, Stone R, Erba H (2018) Results of SWOG 1318: A phase 2 trial of blinatumomab followed by pomp (prednisone, vincristine, methotrexate, 6-mercaptopurine) maintenance in elderly patients with newly diagnosed Philadelphia chromosome negative B-cell acute lymphoblastic leukemia. Blood 132(Suppl 1):33CrossRef

70.

Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM (2018) Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage. Cancer 124(20):4044–4055. https://doi.org/10.1002/cncr.31720CrossRefPubMedPubMedCentral

71.

Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, Rupertus K, Kanz L, Libicher M, Nagorsen D, Zugmaier G, Klinger M, Wolf A, Dorsch B, Quednau BD, Schmidt M, Scheele J, Baeuerle PA, Leo E, Bargou RC (2016) Bispecific T-cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol 34(10):1104–1111. https://doi.org/10.1200/jco.2014.59.1586CrossRefPubMed

72.

Duell J, Zugmaier G, Eisele F, Brüggemann M, Kufer P, Einsele H, Topp M (2019) Treatment of R/R Burkitt lymphoma with blinatumomab is feasible and induced a long lasting complete remission. Paper presented at the European Hematology Association, May 16

73.

Aldoss I, Song J, Stiller T, Nguyen T, Palmer J, O'Donnell M, Stein AS, Marcucci G, Forman S, Pullarkat V (2017) Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol 92(9):858–865. https://doi.org/10.1002/ajh.24783CrossRefPubMed

74.

Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'Brien S, Kantarjian H, Topp MS (2018) Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression. Am J Hematol 93(3):371–374. https://doi.org/10.1002/ajh.24987CrossRefPubMed

75.

Li X, Chen W (2019) Mechanisms of failure of chimeric antigen receptor T-cell therapy. Curr Opin Hematol 26(6):427–433. https://doi.org/10.1097/moh.0000000000000548CrossRefPubMedPubMedCentral

76.

Kotrova M, Pal K, Darzentas N, Duell J, Schroeder M, Neumann M, Bastian L, Franke A, Baldus CD, Topp MS, Brüggemann M (2019) CD19 mutation frequency after blinatumomab treatment is lower than after CAR T-cells treatment. Presented at the 24th European Hematology Association (EHA) Congress; June 15, 2019; Amsterdam, The Netherlands. Abstract PS942

77.

Ruella M, Maus MV (2016) Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J 14:357–362. https://doi.org/10.1016/j.csbj.2016.09.003CrossRefPubMedPubMedCentral

78.

Köhnke T, Krupka C, Tischer J, Knösel T, Subklewe M (2015) Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol 8:111. https://doi.org/10.1186/s13045-015-0213-6CrossRefPubMedPubMedCentral

79.

Feucht J, Kayser S, Gorodezki D, Hamieh M, Döring M, Blaeschke F, Schlegel P, Bösmüller H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T (2016) T-cell responses against CD19⁺ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 7(47):76902–76919. https://doi.org/10.18632/oncotarget.12357CrossRefPubMedPubMedCentral

80.

Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, Rasche L, Hartmann E, Dandekar T, Einsele H, Topp MS (2017) Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia 31(10):2181–2190. https://doi.org/10.1038/leu.2017.41CrossRefPubMedPubMedCentral

81.

Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, Yang Y, Chien CD, Seif AE, Lei H, Song YK, Khan J, Lee DW, Mackall CL, Gardner RA, Jensen MC, Shern JF, Fry TJ (2016) CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun 7:12320. https://doi.org/10.1038/ncomms12320CrossRefPubMedPubMedCentral

82.

Rayes A, McMasters RL, O'Brien MM (2016) Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer 63(6):1113–1115. https://doi.org/10.1002/pbc.25953CrossRefPubMed

83.

Zoghbi A, zur Stadt U, Winkler B, Müller I, Escherich G (2017) Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement. Pediatr Blood Cancer 64(11):e26594. https://doi.org/10.1002/pbc.26594CrossRef

84.

Brown P, Pieters R, Biondi A (2019) How I treat infant leukemia. Blood 133(3):205–214. https://doi.org/10.1182/blood-2018-04-785980CrossRefPubMed

85.

Cuneo A, Balboni M, Piva N, Carli MG, Tomasi P, Previati R, Negrini M, Scapoli G, Spanedda R, Castoldi G (1994) Lineage switch and multilineage involvement in two cases of pH chromosome-positive acute leukemia: evidence for a stem cell disease. Haematologica 79(1):76–82PubMed

86.

Delea TE, Amdahl J, Boyko D, Hagiwara M, Zimmerman ZF, Franklin JL, Cong Z, Hechmati G, Stein A (2017) Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. J Med Econ 20(9):911–922. https://doi.org/10.1080/13696998.2017.1344127CrossRefPubMed

87.

Nelson R (2014) New leukemia drug tops the charts with a $178,000 price tag. Medscape Medical News

88.

Pagliarulo N (2017) In historic first, FDA approves Novartis CAR-T therapy. BioPharmaDive, Aug 30th

89.

Mayerhoff L, Lehne M, Hickstein L, Salimullah T, Prieur S, Thomas SK, Zhang J (2019) Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany. J Comp Eff Res 8(2):121–131. https://doi.org/10.2217/cer-2018-0100CrossRefPubMed

90.

Leukemia & Lymphoma Society (2018) Facts about chimeric antigen receptor (CAR) T-cell therapy. https://www.lls.org/sites/default/files/National/USA/Pdf/Publications/FSHP1_CART_Factsheet_June2018_FINAL.pdf. Accessed December 12 2019

91.

Maude SL, Shpall EJ, Grupp SA (2014) Chimeric antigen receptor T-cell therapy for ALL. Hematol Am Soc Hematol Educ Program 2014(1):559–564. https://doi.org/10.1182/asheducation-2014.1.559CrossRef

92.

Viardot A, Bargou R (2018) Bispecific antibodies in haematological malignancies. Cancer Treat Rev 65:87–95. https://doi.org/10.1016/j.ctrv.2018.04.002CrossRefPubMed

93.

Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA, Kron B, Russo A, Lehmann N, Roth L, Fehr EM, Attig S, Hohberger A, Kindler T, Faber J (2017) CD19 Isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother (Hagerstown, Md : 1997) 40(5):187–195. https://doi.org/10.1097/cji.0000000000000169CrossRefPubMedCentral

94.

Mejstríková E, Hrusak O, Borowitz MJ, Whitlock JA, Brethon B, Trippett TM, Zugmaier G, Gore L, von Stackelberg A, Locatelli F (2017) CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J 7(12):659. https://doi.org/10.1038/s41408-017-0023-xCrossRefPubMedPubMedCentral

95.

Correnti CE, Laszlo GS, de van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, Gudgeon CJ, Bates OM, Olson JM, Mehlin C, Walter RB (2018) Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia 32(5):1239–1243. https://doi.org/10.1038/s41375-018-0014-3CrossRefPubMedPubMedCentral

96.

Habib S, Tariq SM, Tariq M (2019) Chimeric antigen receptor-natural killer cells: the future of cancer immunotherapy. Ochsner J 19(3):186–187. https://doi.org/10.31486/toj.19.0033CrossRefPubMedPubMedCentral

97.

Aldoss I, Forman SJ (2020) How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. Blood 135(11):804–813. https://doi.org/10.1182/blood.2019002132CrossRefPubMed

98.

Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, Wu YN, Deng ZL, Zhang YL, Liu SH, Wu T, Lu PH, Lu DP, Chang AH, Tong CR (2017) High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia 31(12):2587–2593. https://doi.org/10.1038/leu.2017.145CrossRefPubMed

99.

Lee DW III, Stetler-Stevenson M, Yuan CM, Shah NN, Delbrook C, Yates B, Zhang H, Zhang L, Kochenderfer JN, Rosenberg SA, Fry TJ, Stroncek D, Mackall CL (2016) Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation. Blood 128(22):218. https://doi.org/10.1182/blood.V128.22.218.218CrossRef

100.

Brown PA, Ji L, Xu X, Devidas M, Hogan L, Borowitz MJ, Raetz EA, Zugmaier G, Sharon E, Gore L, Whitlock JA, Pulsipher MA, Hunger SP, Loh ML (2019) A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from children's oncology group study AALL1331. Blood 134(Supplement_2):LBA-1-LBA-1. https://doi.org/10.1182/blood-2019-132435CrossRef

Title: Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
Authors: Andreas Viardot
Franco Locatelli
Julia Stieglmaier
Faraz Zaman
Elias Jabbour
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keywords: Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
CAR T-Cell Therapy
Blinatumomab
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Cytostatic Therapy
Published in: Annals of Hematology / Issue 10/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04221-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2020

Histiocytic sarcoma progressing from follicular lymphoma and mimicking acquired hemophagocytic lymphohistiocytosis

A 30-month-old boy with aplastic anemia caused by electrocution

Long non-coding RNAs and MYC association in hematological malignancies

Tacrolimus ameliorates thrombocytopenia in an ITP mouse model

Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network

Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page